Upsher-Smith launches Qudexy XR

MAPLE GROVE, Minn. — Upsher-Smith Labs announced the launch of Qudexy XR (topiramate) extended-release capsules, a once-a-day antiepileptic drug engineered to provide a smooth pharmacokinetic profile.

The drug, which was approved by the Food and Drug Administration in March, offers patients flexibility, the company said. All strengths of Qudexy XR may be swallowed whole or administered by opening the capsule and sprinkling the contents on a spoonful of soft food.

"The launch of our first branded product within our central nervous system portfolio marks a significant milestone in Upsher-Smith's history and demonstrates our focus on developing medications that can make a meaningful difference in people's lives," said Bill Pullman, MB, BS, Phd, FRACP and chief scientific officer of Upsher-Smith. "We are pleased to bring this product forward to treat specific seizure disorders and offer another treatment option to the epilepsy community."

Qudexy XR is available in 25 mg, 50 mg, 100 mg, 150 mg and 200 mg dosage strengths.